CSF and plasma p-tau181 as biomarker for Alzheimer's disease: validation, cutoff values, comparison with p-tau217, and clinical utility
Phosphorylated tau at threonine 181 (p-tau181) is one of the most extensively validated CSF and plasma biomarkers for Alzheimer's disease. It specifically reflects cerebral tau pathology and has become a cornerstone of the AT(N) research framework for AD diagnosis and staging[@karikari_pta181]. As the first p-tau species to gain widespread clinical adoption, p-tau181 bridges the gap between research biomarkers and clinical practice, enabling detection of tau pathology years before clinical symptoms emerge[@blennow_pta181].
The biomarker demonstrates excellent performance in distinguishing Alzheimer's disease from other neurodegenerative conditions, with high specificity for AD-type tau pathology as confirmed by tau PET neuroimaging. Its elevation correlates strongly with Braak staging of neurofibrillary tangle pathology, making it a reliable proxy for established neuropathological assessments that were previously accessible only at autopsy[@milan_pta181].
Tau is a microtubule-associated protein primarily expressed in neurons where it stabilizes axonal microtubules. The protein is encoded by the MAPT gene on chromosome 17q21.31 and exists as six isoforms generated by alternative mRNA splicing. In AD and related tauopathies, tau becomes hyperphosphorylated at multiple sites, causing it to dissociate from microtubules, aggregate into paired helical filaments, and form neurofibrillary tangles[@blennow_pta181].
Phosphorylation at threonine 181 occurs early in the disease process. The p-tau181 epitope is particularly sensitive to pathologically relevant conformational changes in tau, making it an excellent indicator of early tau pathology. CSF p-tau181 rises in parallel with amyloid-beta deposition, as demonstrated by cross-sectional and longitudinal studies in both autosomal dominant AD and sporadic late-onset AD[@lehallier_pta181].
CSF p-tau181 increases through several interconnected mechanisms[@jove_pta181]:
The temporal relationship between amyloid-beta accumulation and p-tau181 elevation suggests a mechanistic link, where amyloid pathology drives tau phosphorylation through kinase activation (GSK3-beta, CDK5) and phosphatase inhibition (PP2A), leading to the characteristic AD trajectory of amyloid followed by tau[@blennow_pta181].
p-tau181 is typically measured using automated chemiluminescence immunoassay platforms. The two most widely used methods are[@oeckl_pta181]:
Roche Elecsys p-tau181 — A fully automated electrochemiluminescence immunoassay with excellent precision and turnaround time. Widely adopted in clinical research and increasingly used in specialized clinical laboratories. The assay uses two monoclonal antibodies targeting the p-tau181 epitope specifically.
Lumipulse G p-tau181 — Fujirebio's automated platform providing high-throughput measurement. Well-correlated with Elecsys and used extensively in both research and clinical settings across Europe and Japan.
Simoa p-tau181 — Quanterix's digital immunoassay platform offering superior sensitivity, useful for plasma measurements where concentration is lower than in CSF.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides highest specificity by directly measuring p-tau181 peptide sequences. These methods offer[@oeckl_pta181]:
Mass spec-based methods are increasingly used in reference laboratory settings and for standardization of commercial immunoassays.
| Factor | Recommendation | Impact |
|---|---|---|
| Collection tube | Polypropylene or silicone-coated | Minimizes adsorption |
| Centrifugation | 2,000 x g for 15 min at 4°C | Clears cells and debris |
| Storage temperature | -80°C for >3 months | Preserves phosphorylation |
| Freeze-thaw cycles | Maximum 3 cycles | Prevents degradation |
| Sample volume | 0.5 mL minimum | Sufficient for duplicate |
p-tau181 demonstrates excellent accuracy for AD diagnosis across multiple cohorts and platforms[@karikari_pta181]:
CSF p-tau181 (Elecsys):
| Cohort | Sensitivity | Specificity | AUC |
|---|---|---|---|
| ADNI (n=1,532) | 88-92% | 84-87% | 0.93 |
| BioFINDER | 90-94% | 85-89% | 0.95 |
| Knight ADRC | 87-91% | 83-88% | 0.92 |
Plasma p-tau181:
| Cohort | Sensitivity | Specificity | AUC |
|---|---|---|---|
| BioFINDER | 89-93% | 87-91% | 0.94 |
| ADNI | 85-89% | 82-86% | 0.90 |
| SCIPP | 87-91% | 84-88% | 0.91 |
CSF p-tau181 (Elecsys):
| Concentration | Interpretation | Clinical Context |
|---|---|---|
| <40 pg/mL | Normal | Cognitively unimpaired |
| 40-60 pg/mL | Borderline | Requires clinical correlation |
| >60 pg/mL | Elevated | Consistent with AD pathology |
Plasma p-tau181:
| Concentration | Interpretation | Clinical Context |
|---|---|---|
| <1.8 pg/mL | Normal | Cognitively unimpaired |
| 1.8-2.7 pg/mL | Borderline | Requires CSF confirmation |
| >2.7 pg/mL | Elevated | Consistent with AD pathology |
Cutoff values vary by laboratory and assay platform. Each laboratory should establish reference ranges using locally recruited cognitively normal controls, then verify against published multicenter values. Age-stratified cutoffs improve accuracy in elderly populations where false positive rates increase[@ashford_pta181].
p-tau181 can detect AD pathology in cognitively normal individuals, enabling identification of preclinical disease[@mossine_pta181]:
p-tau181 reliably distinguishes AD from non-AD dementia etiologies[@swiet_pta181]:
| Condition | p-tau181 | Notes |
|---|---|---|
| Alzheimer's disease | Elevated | Highest in typical amnestic AD |
| Frontotemporal dementia | Normal-Low | Key differential; p-tau181 normal even in FTD-tau |
| Dementia with Lewy bodies | Normal-Low | Can be mildly elevated in DLB with co-pathology |
| Vascular dementia | Normal | Typically normal unless mixed AD pathology |
| Normal pressure hydrocephalus | Normal | Rules out AD contribution |
| Parkinson's disease dementia | Normal-Low | Typically lower than AD |
This differential diagnostic utility makes p-tau181 valuable in clinical practice when the clinical presentation is ambiguous between AD and other dementia subtypes.
Longitudinal p-tau181 measurement tracks disease progression[@lehallier_pta181]:
Short-term monitoring (1-2 years):
Long-term monitoring (5+ years):
p-tau181 serves as a pharmacodynamic biomarker for disease-modifying therapies targeting tau and amyloid[@salloway_pta181]:
Anti-amyloid therapies (lecanemab, donanemab):
Anti-tau therapies (semorinemab, zagotenemab):
p-tau217 offers superior performance in several dimensions[@janelidze_pta181]:
| Feature | p-tau181 | p-tau217 |
|---|---|---|
| CSF sensitivity | 92% | 96% |
| CSF specificity | 81% | 87% |
| Plasma assay available | Yes | Yes |
| Plasma performance | Good (AUC 0.91) | Excellent (AUC 0.96) |
| Cost | Lower | Higher |
| Availability | Widespread | Limited (commercial labs) |
| Regulatory status | FDA cleared | FDA cleared |
p-tau217 shows particular advantage in[@theron_pta181]:
However, p-tau181 remains clinically useful because of its wider availability, lower cost, extensive validation data, and adequate performance for most diagnostic scenarios. Many laboratories and clinical trials continue to use p-tau181 as the standard tau biomarker.
p-tau181 fits into the AT(N) classification system[@cummings_pta181]:
An "A+T+" profile confirms AD pathology regardless of neurodegeneration markers. This biomarker-based diagnosis enables identification of AD pathology in individuals with atypical clinical presentations where clinical criteria alone are insufficient.
The combination of p-tau181 and GFAP provides a blood-based biomarker panel covering both amyloid (GFAP) and tau (p-tau181) pathology. This dual-marker approach offers:
APOE4 carriers show higher baseline p-tau181 and faster longitudinal increases[@ashford_pta181]:
p-tau181 increases with normal aging, complicating interpretation in elderly subjects:
| Source of Variability | Magnitude | Mitigation |
|---|---|---|
| Between-lot (immunoassay) | 5-10% | Use lot-verification panels |
| Between-lab | 10-20% | Harmonization protocols |
| Within-subject (biological) | 8-12% | Triplicate sampling |
| Diurnal variation | Minimal | Any time of day acceptable |
p-tau181 elevation in conditions other than AD[@migliaccio_pta181]:
| Disease | p-tau181 Level | Mechanism |
|---|---|---|
| Progressive supranuclear palsy | Normal to mild | Primary 4R tauopathy, different epitope |
| Corticobasal degeneration | Normal to mild | 4R tauopathy, limited p-tau181 response |
| Frontotemporal dementia with MAPT | Normal | Picks up AD pathology, not primary tau |
| Chronic traumatic encephalopathy | Mildly elevated | Mixed AD/tau pathology |
| Down syndrome AD | Elevated | Accelerated AD-type pathology |
The relative specificity of p-tau181 for AD-type 3R/4R mixed tau pathology makes it a useful test to screen for comorbid AD in other neurodegenerative conditions.
Blood-based p-tau181 offers potential for dementia specialist and primary care screening:
International standardization efforts aim to harmonize p-tau181 measurements across platforms:
Emerging technologies may enable rapid p-tau181 measurement:
p-tau181 is a well-validated, widely available biomarker that reflects cerebral tau pathology in Alzheimer's disease. Key points:
p-tau181 continues to serve as a cornerstone biomarker in AD research and clinical practice, with an expanding role as plasma-based testing extends its reach beyond specialized centers.